CRSP - Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
2024-05-03 11:30:00 ET
Summary
- Crispr Therapeutics AG stock has plunged deep into a bear market.
- The FOMO attributed to Crispr's Casgevy approvals is likely dissipated.
- Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile.
- Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly.
- The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up.
I upgraded CRISPR Therapeutics AG ( CRSP ) stock to a Hold rating in late February 2024 after anticipating that the worst seemed over for CRSP . As a reminder, I cautioned investors about chasing after CRSP's surging optimism in late November 2023 as the market assessed the potentially historic approval for Casgevy then....
Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)